Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 10/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.87 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.87 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dordaviprone SCHEMBL29359574 | 1.00 | CLPP (1.00) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| Dordaviprone SCHEMBL29414943 | 0.99 | CLPP (0.98) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| Dordaviprone SCHEMBL31548590 | 0.99 | CLPP (0.98) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| SCHEMBL20173633 | 0.94 | CLPP (0.89) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| SCHEMBL18254991 | 0.94 | CLPP (0.89) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| SCHEMBL26265189 | 0.93 | CLPP (0.88) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| SCHEMBL19222684 | 0.93 | CLPP (0.88) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| SCHEMBL13559495 | 0.93 | CYP3A4 (1.00) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| SCHEMBL30085760 | 0.93 | CYP3A4 (1.00) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| SCHEMBL18254945 | 0.92 | CLPP (0.85) | CLPPCYP3A4GPR132CYP2D6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109133-A1 | 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[l,2-A]PYRIDO[3,4-E] PYRIMIDIN-5 (1 H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FORTHEIR USE IN THERAPY | CHIMERIX, INC. (US) | 2025-04-03 | — | — | US | claimed |
| EP-4516359-A2 | 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY | Oncoceutics, Inc. (US) | 2025-03-05 | — | — | EP | claimed |
| EP-3662910-B1 | PHARMACOPHORE FOR TRAIL INDUCTION | SCRIPPS RESEARCH INST (US) | 2024-09-18 | — | — | EP | claimed |
| WO-2024102447-A1 | USES OF HYDROIMIDAZOPYRIDOPYRIMIDINONE DERIVATIVES FOR MANAGING ANEURYSMS OR OTHER VASCULAR CONDITIONS OR DISEASES | EMORY UNIVERSITY (US) | 2024-05-16 | — | — | WO | claimed |
| US-11891392-B2 | Pharmacophore for trail induction | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-02-06 | — | — | US | claimed |
| CN-111499636-B | Pharmacophores for TRAIL induction | 斯克里普斯研究学院（US） | 2023-01-13 | — | — | CN | claimed |
| US-20180369264-A1 | COMBINATION OF A CARDIAC STEROID AND AN AKT INHIBITOR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISORDERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-12-27 | — | — | US | claimed |
| EP-3393477-A1 | COMBINATION OF A CARDIAC STEROID AND AN AKT INHIBITOR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISORDERS | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2018-10-31 | — | — | EP | claimed |
| WO-2017109778-A1 | COMBINATION OF A CARDIAC STEROID AND AN AKT INHIBITOR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISORDERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2017-06-29 | — | — | WO | claimed |
| US-12630550-B2 | Pharmacophore for trail induction | THE SCRIPPS RESEARCH INSTITUTE (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4684834-A1 | CRYSTALLINE FORMS OF ONCOLOGICALLY ACTIVE IMIPRIDONES AND PROCESS FOR THEIR PREPARATION | BRIU GmbH (DE) | 2026-01-28 | — | — | EP | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025136346-A1 | INDAZOLE CONTAINING COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4516359-A3 | 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY | Oncoceutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2015073072-A1 | 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE | ONCOCEUTICS, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015073109-A1 | 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE, SALTS THEREOF AND METHODS OF USE | ONCOCEUTICS, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015073072-A1 | 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE | ONCOCEUTICS, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20140335048-A1 | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Using the Same in Combination Therapy | ONCOCEUTICS, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140335048-A1 | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Using the Same in Combination Therapy | ONCOCEUTICS, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140335048-A1 | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Using the Same in Combination Therapy | ONCOCEUTICS, INC. (US) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630550-B2 | Pharmacophore for trail induction | STAT3, STAT1, STAT4 | CLPP 995/4885CYP3A4 218/4885GPR132 394/4885 |
| US-20140335048-A1 | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Using the Same in Combination Therapy | TPMT, PAICS, THPO | CLPP 2344/4885CYP3A4 2932/4885GPR132 1718/4885 |
| US-11891392-B2 | Pharmacophore for trail induction | AIFM1, TNFRSF1A, TNFSF10 | CLPP 1369/4885CYP3A4 205/4885GPR132 61/4885 |
| US-20250109133-A1 | 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[l,2-A]PYRIDO[3,4-E] PYRIMIDIN-5 (1 H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FORTHEIR USE IN THERAPY | FOLR2, FOLR1, TYMP | CLPP 3820/4885CYP3A4 79/4885GPR132 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.